TP53 Alterations Associate with Poor Response to Lenvatinib in Patients with Advanced Thyroid Cancer. Cirello V, Colombo C, Tosi D, Manzo A, et al. J Clin Endocrinol Metab 2025 Feb 1:dgaf056. doi: 10.1210.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Cirello V, Colombo C, Tosi D, Manzo A, et al. TP53 Alterations Associate with Poor Response to Lenvatinib in Patients with Advanced Thyroid Cancer. J Clin Endocrinol Metab 2025 Feb 1:dgaf056. doi: 10.1210.
PMID: 39891677